Dr. Mazdak Momeni, MD
Claim this profileWomen's Cancer and Surgical Oncology Center
Studies Ovarian Cancer
Studies Allergic Reaction
2 reported clinical trials
3 drugs studied
Area of expertise
1Ovarian Cancer
2Allergic Reaction
Stage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Mazdak Momeni, MD is currently running
HIPEC
for Recurrent Ovarian Cancer
This is a phase I prospective study with the primary objective to compare the efficacy and safety of Surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of recurrent ovarian, primary peritoneal or fallopian tube cancers. Eligible patients consenting to this protocol will undergo their scheduled surgical procedure. After surgical cytoreduction to a residual disease ≤ 2.5 mm, a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C). At 4-6 weeks after CRS, patients will go on to receive 6 cycles of standard IV platinum-based chemotherapy. The proportion of patients who are without evidence of recurrence will be assessed at 6, 9, 12 and 18 months after the day of surgery.
Recruiting1 award Phase 16 criteria
Dexamethasone Methods
for Preventing Allergic Reactions to Chemotherapy
This trial tests three different ways to prevent allergic reactions in women with gynecologic cancers who are treated with paclitaxel. The methods involve using steroids and antihistamines before the treatment. The goal is to find out which method works best to keep patients safe from allergic reactions. Paclitaxel is a plant product highly active in numerous cancers, but it has a significant incidence of hypersensitivity reactions, which are typically managed with steroids and antihistamines.
Recruiting2 awards Phase 3
More about Mazdak Momeni, MD
Clinical Trial Related8 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mazdak Momeni, MD has experience with
- Carboplatin
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Dexamethasone
Breakdown of trials Mazdak Momeni, MD has run
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mazdak Momeni, MD specialize in?
Mazdak Momeni, MD focuses on Ovarian Cancer and Allergic Reaction. In particular, much of their work with Ovarian Cancer has involved treating patients, or patients who are undergoing treatment.
Is Mazdak Momeni, MD currently recruiting for clinical trials?
Yes, Mazdak Momeni, MD is currently recruiting for 2 clinical trials in Loma Linda California. If you're interested in participating, you should apply.
Are there any treatments that Mazdak Momeni, MD has studied deeply?
Yes, Mazdak Momeni, MD has studied treatments such as Carboplatin, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Dexamethasone.
What is the best way to schedule an appointment with Mazdak Momeni, MD?
Apply for one of the trials that Mazdak Momeni, MD is conducting.
What is the office address of Mazdak Momeni, MD?
The office of Mazdak Momeni, MD is located at: Women's Cancer and Surgical Oncology Center, Loma Linda, California 92354 United States. This is the address for their practice at the Women's Cancer and Surgical Oncology Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.